ATE269078T1 - Piperazin derivate, deren herstellung und deren verwendung in der behandlung von störungen des zentralnervensystems - Google Patents
Piperazin derivate, deren herstellung und deren verwendung in der behandlung von störungen des zentralnervensystemsInfo
- Publication number
- ATE269078T1 ATE269078T1 AT01986458T AT01986458T ATE269078T1 AT E269078 T1 ATE269078 T1 AT E269078T1 AT 01986458 T AT01986458 T AT 01986458T AT 01986458 T AT01986458 T AT 01986458T AT E269078 T1 ATE269078 T1 AT E269078T1
- Authority
- AT
- Austria
- Prior art keywords
- disorders
- treatment
- production
- nervous system
- central nervous
- Prior art date
Links
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical class C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 title 1
- 210000003169 central nervous system Anatomy 0.000 title 1
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25330100P | 2000-11-28 | 2000-11-28 | |
| US29781401P | 2001-06-13 | 2001-06-13 | |
| PCT/US2001/043160 WO2002044142A2 (en) | 2000-11-28 | 2001-11-27 | Piperazine derivatives, their preparation and their use for treating central nervous system (cns) disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE269078T1 true ATE269078T1 (de) | 2004-07-15 |
Family
ID=26943115
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01986458T ATE269078T1 (de) | 2000-11-28 | 2001-11-27 | Piperazin derivate, deren herstellung und deren verwendung in der behandlung von störungen des zentralnervensystems |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US6469007B2 (de) |
| EP (1) | EP1339406B1 (de) |
| JP (1) | JP4198989B2 (de) |
| KR (1) | KR100835552B1 (de) |
| CN (1) | CN100352437C (de) |
| AR (1) | AR035603A1 (de) |
| AT (1) | ATE269078T1 (de) |
| AU (2) | AU2002237654B2 (de) |
| BR (1) | BR0115609A (de) |
| CA (1) | CA2428039C (de) |
| DE (1) | DE60103927T2 (de) |
| DK (1) | DK1339406T3 (de) |
| EA (1) | EA005925B1 (de) |
| ES (1) | ES2222401T3 (de) |
| HU (1) | HUP0400551A2 (de) |
| IL (1) | IL156098A0 (de) |
| MX (1) | MXPA03004677A (de) |
| NO (1) | NO325501B1 (de) |
| NZ (1) | NZ526150A (de) |
| PL (1) | PL363219A1 (de) |
| PT (1) | PT1339406E (de) |
| TR (1) | TR200401546T4 (de) |
| TW (1) | TWI224102B (de) |
| WO (1) | WO2002044142A2 (de) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6432826B1 (en) * | 1999-11-29 | 2002-08-13 | Applied Materials, Inc. | Planarized Cu cleaning for reduced defects |
| US20060223824A1 (en) * | 2000-11-28 | 2006-10-05 | Wyeth | Serotonergic agents |
| US20060287335A1 (en) * | 2000-11-28 | 2006-12-21 | Wyeth | Serotonergic agents for treating sexual dysfunction |
| US7504395B2 (en) * | 2001-07-20 | 2009-03-17 | Psychogenics, Inc. | Treatment for attention-deficit hyperactivity disorder |
| US7091349B2 (en) | 2002-03-12 | 2006-08-15 | Wyeth | Process for synthesizing N-aryl piperazines with chiral N′-1-[benzoyl(2-pyridyl)amino]-2-propane substitution |
| MXPA04008729A (es) | 2002-03-12 | 2005-07-13 | Wyeth Corp | Proceso para sintetizacion de piperazinas n-arilicas quirales. |
| US7361773B2 (en) | 2002-03-12 | 2008-04-22 | Wyeth | Preparation of N1-(2'-pyridyl)-1,2-propanediamine sulfamic acid and its use in the synthesis of biologically active piperazines |
| CN101492383A (zh) | 2002-03-12 | 2009-07-29 | 惠氏公司 | 制备手性1,4-二取代哌嗪的方法 |
| GB0219961D0 (en) * | 2002-08-28 | 2002-10-02 | Pfizer Ltd | Oxytocin inhibitors |
| US20040192730A1 (en) * | 2003-03-13 | 2004-09-30 | Dynogen Pharmaceuticals, Inc. | Methods of using compounds with combined 5-HT1A and SSRI activities as-needed to treat sexual dysfunction |
| US20050215561A1 (en) * | 2004-03-19 | 2005-09-29 | Krishnendu Ghosh | Pharmaceutical dosage forms and compositions |
| US20050209245A1 (en) * | 2004-03-19 | 2005-09-22 | Wyeth | Process for preparing N-aryl-piperazine derivatives |
| US20070099931A1 (en) * | 2004-03-19 | 2007-05-03 | Wyeth | Pharmaceutical dosage forms and compositions |
| KR100646337B1 (ko) * | 2004-06-30 | 2006-11-23 | 주식회사 롯데기공 | 보일러의 누수 감지방법 |
| EP2218736A1 (de) * | 2004-10-15 | 2010-08-18 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Implantate, die mit amphipathischen helikalen Peptiden beschichtet sind, die mehrere Domaenen enthalten, und Verfahren zu ihrer Verwendung |
| KR20070112797A (ko) * | 2005-03-01 | 2007-11-27 | 와이어쓰 | 결정질 및 비결정질4-시아노-n-((2r)-2-[4-(2,3-디히드로-벤조[1,4]디옥신-5-일)-피페라진-1-일]-프로필)-n-피리딘-2-일-벤즈아미드염산염 |
| TW200800959A (en) * | 2005-06-10 | 2008-01-01 | Wyeth Corp | Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor |
| MX2007015772A (es) * | 2005-06-17 | 2008-02-22 | Wyeth Corp | Compuestos utiles como inhibidores de serotonina y agonistas y antagonistas de 5-ht-1a. |
| EP1993527A4 (de) * | 2006-01-26 | 2009-08-05 | Univ Rochester | Hemmung der amyloid-beta-peptid-/rage-interaktion an der blut-hirn-schranke |
| TW200808741A (en) * | 2006-06-09 | 2008-02-16 | Wyeth Corp | 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts |
| TW200808740A (en) * | 2006-06-09 | 2008-02-16 | Wyeth Corp | Succinate salts of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline and crystalline forms thereof |
| TW200811144A (en) * | 2006-06-09 | 2008-03-01 | Wyeth Corp | Crystalline forms of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline |
| TW200831096A (en) * | 2006-11-28 | 2008-08-01 | Wyeth Corp | Metabolites of 5-Fluoro-8-{4-[4-(6-methoxyquinolin-8-yl)piperazin-1-yl]piperidin-1-yl} quinoline and methods of preparation and uses thereof |
| TW200901974A (en) | 2007-01-16 | 2009-01-16 | Wyeth Corp | Compounds, compositions, and methods of making and using them |
| WO2009129263A1 (en) * | 2008-04-15 | 2009-10-22 | The Government Of The Usa As Represented By The Secretary Of The Department Of Health & Human Serv. | Peptides promoting lipid efflux via abca1 and activating a lipoprotein lipase |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX9201991A (es) | 1991-05-02 | 1992-11-01 | Jonh Wyeth & Brother Limited | Derivados de piperazina y procedimiento para su preparacion. |
| GB9514901D0 (en) | 1995-07-20 | 1995-09-20 | American Home Prod | Piperazine derivatives |
-
2001
- 2001-11-13 US US10/010,575 patent/US6469007B2/en not_active Expired - Fee Related
- 2001-11-27 JP JP2002546512A patent/JP4198989B2/ja not_active Expired - Fee Related
- 2001-11-27 ES ES01986458T patent/ES2222401T3/es not_active Expired - Lifetime
- 2001-11-27 NZ NZ526150A patent/NZ526150A/en unknown
- 2001-11-27 AT AT01986458T patent/ATE269078T1/de not_active IP Right Cessation
- 2001-11-27 CN CNB018196853A patent/CN100352437C/zh not_active Expired - Fee Related
- 2001-11-27 AR ARP010105502A patent/AR035603A1/es not_active Application Discontinuation
- 2001-11-27 WO PCT/US2001/043160 patent/WO2002044142A2/en not_active Ceased
- 2001-11-27 TW TW090129285A patent/TWI224102B/zh not_active IP Right Cessation
- 2001-11-27 BR BR0115609-8A patent/BR0115609A/pt not_active Application Discontinuation
- 2001-11-27 PL PL01363219A patent/PL363219A1/xx not_active Application Discontinuation
- 2001-11-27 CA CA2428039A patent/CA2428039C/en not_active Expired - Fee Related
- 2001-11-27 HU HU0400551A patent/HUP0400551A2/hu unknown
- 2001-11-27 MX MXPA03004677A patent/MXPA03004677A/es active IP Right Grant
- 2001-11-27 DE DE60103927T patent/DE60103927T2/de not_active Expired - Lifetime
- 2001-11-27 PT PT01986458T patent/PT1339406E/pt unknown
- 2001-11-27 IL IL15609801A patent/IL156098A0/xx unknown
- 2001-11-27 EP EP01986458A patent/EP1339406B1/de not_active Expired - Lifetime
- 2001-11-27 EA EA200300619A patent/EA005925B1/ru not_active IP Right Cessation
- 2001-11-27 KR KR1020037007064A patent/KR100835552B1/ko not_active Expired - Fee Related
- 2001-11-27 DK DK01986458T patent/DK1339406T3/da active
- 2001-11-27 AU AU2002237654A patent/AU2002237654B2/en not_active Ceased
- 2001-11-27 TR TR2004/01546T patent/TR200401546T4/xx unknown
- 2001-11-27 AU AU3765402A patent/AU3765402A/xx active Pending
-
2002
- 2002-08-14 US US10/218,251 patent/US6586436B2/en not_active Expired - Fee Related
-
2003
- 2003-05-20 US US10/441,536 patent/US7026320B2/en not_active Expired - Fee Related
- 2003-05-27 NO NO20032390A patent/NO325501B1/no not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60103927D1 (de) | Piperazin derivate, deren herstellung und deren verwendung in der behandlung von störungen des zentralnervensystems | |
| DE602004015269D1 (de) | Piperazin derivate und ihre verwendung für die behandlung von neurologischen und psychiatrischen krankheiten. | |
| ATE294171T1 (de) | Phenylsulfonyl-1,3-dihydro-2h-indol-2-on derivate,deren herstellung und deren therapeutische verwendung | |
| DE60319865D1 (de) | Substituierte amin-derivate und deren verwendung zur behandlung von angionese-bedingten erkrankungen | |
| DE60234116D1 (de) | Piperidin mch antagonisten und ihre verwendung in der behandlung von obesität und störungen des zentralnervensystems | |
| NO20014303D0 (no) | JAK-3-inhibitorer for behandling av allergiske lidelser | |
| DE60234269D1 (de) | Substituierte aryl 1,4-pyrazin derivate | |
| DE60233265D1 (de) | 5-sulfanyl-4h-1,2,4-triazolderivate und deren verwendung zur behandlung von somatostatine vermittelten krankheiten | |
| NO20031903L (no) | Nye amidoalkylpiperidin- og amidoalkylpiperazinderivater for anvendelse vedbehandling av nervesystemlidelser | |
| NO20022585L (no) | Pyrrolidinacetamidderivat alene eller i kombinasjon for behandling av forstyrrelser i sentralnervesystemet | |
| ATE415392T1 (de) | Pyrimidinonderivate und deren verwendung bei der behandlung von atherosklerose | |
| EE200200442A (et) | Piperasiini ja piperidiini derivaadid neuronaalsete kahjustuste raviks | |
| ATE411801T1 (de) | Verwendung von oxindol-derivaten bei der behandlung von demenzbedingten krankheiten, alzheimer-krankheit und erkrankungen im zusammenhang mit glykogen-synthase-kinase-3 | |
| DE60137307D1 (de) | Substituierte sapogenine und ihre verwendung | |
| DE69833297D1 (de) | Substituierte Pyridylmethylpiperazin- und piperidinderivate, deren Herstellung und deren Verwendung in der Behandlung von Erkrankungen des Zentralnervensystems (ZNS) | |
| ATE276245T1 (de) | Indolderivate und deren verwendung zur behandlung von u.a. osteoporosis | |
| DE60318839D1 (de) | 2,6-chinolinyl- und 2,6-naphthylderivate und deren verwendungen zur behandlung von vla-4 bezogenen krankheiten | |
| DE69901177D1 (de) | Platinkomplex, dessen herstellung und dessen therapeutische verwendung | |
| ATE263564T1 (de) | Verwendung von 1-(4-(5-cyanoindol-3yl)butyl)-4-(2-carbamoylben ofuran-5-yl)piperazin und dessen physiologisch akzeptablen salzen zur behandlung von bipolaren krankheiten und manie | |
| ATE275400T1 (de) | Verwendung von melatonin zur behandlung der androgenetischen und diffusen alopezie vom weiblichen typ | |
| ATE357438T1 (de) | 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems | |
| ATE336491T1 (de) | Piperazinylacylpiperidinderivate, deren herstellung und deren therapeutische anwendung | |
| DE69523654D1 (de) | Verwendung von Ascorbyl-gamma-Linolenat und von Ascorbyl-dihomo-gamma-linolenat zur Behandlung von Asthma, Krebs, kardiovaskulären und inflammatorischen Erkrankungen | |
| DE60205894D1 (de) | 4-(phenyl-piperidin-4-ylidenmethyl)-benzamid-derivate und deren verwendung zur behandlung von schmerzen, angst oder gastrointestinalen störungen | |
| DE50114605D1 (de) | No-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1339406 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |